Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning

Experimental Hematology & Oncology
Masahiro Imamura, Akio Shigematsu

Abstract

The outcomes of adult acute lymphoblastic leukemia (ALL) patients with chemotherapy or autologous hematopoietic stem cell transplantation (HSCT) are unsatisfactory. Therefore, allogeneic (allo) HSCT has been applied to those patients in first complete remission (CR1), and has shown a long-term survival rate of approximately 50 %. In terms of myeloablative conditioning (MAC) regimen, higher dose of cyclophosphamide (CY) and total body irradiation (TBI) (the standard CY + TBI) has been generally applied to allo HSCT. Other MAC regimens such as busulfan-based or etoposide-based regimens have also been used. Among those, medium-dose etoposide (ETP) in addition to the standard CY + TBI conditioning regimen appears to be promising for allo HSCT in adult ALL when transplanted in ALL patients aged under 50 years in CR1 and also in CR2, showing an excellent outcome without increasing relapse or transplant-related mortality (TRM) rates. By contrast, reduced-intensity conditioning (RIC) regimens have also been applied to adult ALL patients and favorable outcomes have been obtained; however, relapse and TRM rates remain high. Therefore, an allo HSCT conditioning regimen which deserves further study for adult ALL patients aged under 50 year...Continue Reading

References

Jun 1, 1995·Clinical Immunology and Immunopathology·L M SlaterJ T Reynolds
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C SebbanD Maraninchi
Jul 20, 2002·Blood·Norbert SchmitzUNKNOWN European Group for Blood and Marrow Transplantation
Sep 20, 2002·Blood·Hervé DombretUNKNOWN Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group)
Jul 19, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kristine DoneyRainer Storb
Sep 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier ThomasDenis Fiere
Nov 27, 2004·The New England Journal of Medicine·Mary J LaughlinMary M Horowitz
Nov 27, 2004·The New England Journal of Medicine·Vanderson RochaUNKNOWN Eurocord-Netcord Registry
Mar 4, 2006·International Journal of Hematology·Masahiro ImamuraYoshihisa Kodera
Aug 19, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Seok LeeChun-Choo Kim
Nov 6, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anja BorgmannUNKNOWN ALL-REZ BFM Study Group
Apr 16, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Akio ShigematsuMasahiro Imamura
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Anthony S SteinStephen J Forman
Jun 19, 2010·The Lancet Oncology·Mary EapenUNKNOWN National Cord Blood Program of the New York Blood Center
Aug 27, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Partow KebriaeiRichard Champlin
Oct 9, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·James TraceyMary Eapen
Jun 12, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yasuo MorishimaUNKNOWN International Histocompatibility Working Group in Hematopoietic Cell Transplantation

❮ Previous
Next ❯

Citations

Jan 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yongxian HuHe Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.